| INTRODUCTION
Neuroligins are postsynaptic cell adhesion molecules that are involved in the NRXN-NLGN-SHANK pathway, most likely associated with synaptogenesis and the balance between synapse excitation and inhibition (Bang & Owczarek, 2013; Mackowiak, Mordalska, & Wedzony, 2014) .
Accumulating evidence suggests involvement of the neuroligin family in autism and other neuropsychiatric disorders (Jamain et al., 2003; Laumonnier et al., 2004; Lawson-Yuen, Saldivar, Sommer, & Picker, 2008; Philippe et al., 1999; Sindi, Tannenberg, & Dodd, 2014; Thomas et al., 1999) . In 2003, a mutation in neuroligin 3 (NLGN3; p.R451C) and a mutation in neuroligin 4X (NLGN4X; p.D396 fs) were reported in two unrelated Swedish autism families (Jamain et al., 2003) . Since then, several other mutations in the NLGN3, NLGN4X, and NLGN4Y genes have been reported to be related to autism (Chih, Afridi, Clark, & Scheiffele, 2004; Daoud et al., 2009; Kuroda et al., 2014; Laumonnier et al., 2004; Lawson-Yuen et al., 2008; Talebizadeh et al., 2006; Yan et al., 2005 Yan et al., , 2008 . In vitro and in vivo experiments have indicated that the autism-related neuroligin mutations may affect synapse maturation and function. (Bemben et al., 2015; Chih et al., 2004; Ey, Leblond, & Bourgeron, 2011; Jaramillo, Liu, Pettersen, Birnbaum, & Powell, 2014; Zhang et al., 2009 ).
In our previous study, we identified one NLGN3 and three NLGN4X variants (p.G426S in NLGN3; p.G84R, p.Q162K, and p.A283T in NLGN4X) (Xu et al., 2014) . All four were missense and located in the conserved extracellular noncatalytic acetylcholinesterase homology domain, which is essential for binding to neurexin and triggering synaptic activity. Prediction of the effect of these substitutions using MutationTaster (http://www.mutationtaster.org/), Poly-Phen-2 (http://genetics.bwh.harvard.edu/pph2/), and SIFT (http://sift.jcvi.
org/) revealed that p.G84R and p.A283T were "probably damaging"; however, p.G426S and p.Q162K were likely to be "benign" (Xu et al., 2014) . The four variants might impair the functional properties of neuroligin related to synaptic homeostasis, thereby increasing predisposition to autism. To test this hypothesis, here we analyzed the functional effect of these four missense variants.
| MATERIAL AND METHODS

| Plasmids and mutagenesis
Vectors expressing unmodified human neuroligin 3 (NM_018977.2) and neuroligin 4X (NM_020742.2) were subcloned into a green fluorescent protein (GFP)-tagged (C terminal, pEGFP-N1) vector, and verified by sequencing. Vectors expressing a soluble IgG-NX1β fusion protein (in a pCMV5 backbone) were provided by Professor Thomas C. Südhof (Zhang et al., 2009 constructed by introducing the relevant point mutation using a Agilent Native Pfu QuickChange Kit (Agilent, US, Santa Clara, California).
The molecular weight for all of the GFP-NL3 fusion proteins is ≈110 kDa(including the wild-type protein, mutant protein, and the positive-control). The molecular weight for the GFP-NL4-WT and the three GFP-NL4-mutant fusion proteins is ≈120 kDa. The molecular weight for the GFP-NL4-R87W fusion proteins is ≈90 kDa. The molecular weight for the loading control beta-actin is ≈42 kDa. 
| Cell culture and transfections
| Assay of mutant protein degradation pathway
| Immunofluorescence
Stable HEK293 Lakes, New Jersey) antibodies were used. Images were captured using a Leica TCS SP5 confocal microscope.
| Assay of cell surface biotinylation
Stable HEK293 cell lines were grown on coverglasses in 6-cm plate.
After 24 h, the culture medium was removed and the cells washed twice with 1× PBS. For surface biotinylations, the cells were washed twice with ice-cold PBS, pH 8.0 and incubated with 2 mg/ml sulfo-NHS-LC-biotin (Pierce) in PBS, pH 8.0 for 30 min on ice. in at 4°C) and the beads washed 3-5 times with 1× PBS (with protease inhibitors).
Then, 100 μl Quenching Solutio (with protease inhibitors) was added to terminate reaction. Subsequently, cells were washed with 1× PBS (with protease inhibitors). The proteins were extracted for 10 min at 4°C in Lysis Buffer (PBS containing 1% Triton X-100, 0.2% SDS, 5 mmol/L EDTA, 2 mmol/L DTT, and protease inhibitors), and the lysate saved in 1.5-ml centrifuge tubes. Insoluble material was removed by centrifugation (1,000g for 5 min), and the supernatant was quantified by Pierce BCA protein assay and retained for the biotin labeling. The 100 μl NeutrAvidin Agarose (Thermo Fisher Scientific) were washed three times with 1 ml 1× PBS (with protease inhibitors) by centrifugation (1,000g for 3 min). Then part of the supernatant (including 500 μg protein) was mixed with the NeutrAvidin Agarose and rotated at 4°C for at least 6 hr. The supernatant was removed by centrifugation
(1,000g for 4 min at 4°C) and the beads washed 3-5 times in 1× PBS (with protease inhibitors) by centrifugation (1,000g for 4 min at 4°C). final concentrati of 0.1 g/L; Sigma, US, Santa Clara, California) plus 1 mol/L HEPES-NaOH were added. Insoluble material was removed by centrifugation (2,500g for 20 min), and the supernatant was retained for the purification assay. Each binding assay used 10 μl IgG beads. The beads were washed three times with 1 ml 1× PBS (with protease inhibitors) by centrifugation (6,500g for 5 min). Then the supernatant was mixed with the beads and rotated at 4°C for at least 6 hr. The supernatant was removed by centrifugation (6,500g
for 20 min at 4°C) and the beads washed 3-5 times in 1× PBS (with protease inhibitors). Then elution buffer (glycine, 100 mmol/L) was added and the tubes rotated at room temperature for 30 min.
The IgG beads were removed by centrifugation (6,500g for 5 min at 4°C). Neutralizing buffer (2 mol/L Tris-HCl, pH 8.0) was added to the supernatant and it was saved for immunoprecipitation (IP).
Western 
F I G U R E 2
The two variants did not block the transport of neuroligin from ER to cell membrane. HEK293 cells expressing GFP-tagged wild-type neuroligin (NL3-WT and NL4-WT), mutant neuroligin (NL3-G426S and NL4-Q162K), and positive control (NL3-R451C and NL4-R87W) were immunostained with antibodies against the GFP tag (first column, green) and against the Golgi-marker GM130 (second column, red). The nucleus was labeled by DAPI (4′,6-diamidino-2-phenylindole) (third column, blue). Both the wild-type and mutant neuroligin are transported efficiently to the cell surface, whereas the positive control accumulates in the Golgi body, as confirmed by the overlap with the Golgi body-resident protein calnexin. The scale bar is 5 mm
| Neurexin 1-neuroligin interaction assay
The interaction between neurexin 1 and neuroligin was tested by 
| Statistical analysis
In this study, all statistical analysis was performed using Prism 5 soft- 
| RESULTS
To study the functional effect of the four mutations, we analyzed the expression level, subcellular localization, degradation, and interaction with neurexin, using in vitro experiments in HEK293 cells stably expressing wild-type or mutant neuroligin 3 or neuroligin 4X.
Immunofluorescence showed that mutant neuroligin 3 and neuroligin 4X did not colocalized with calnexin and GM130. In contrast, the two positive control mutant proteins colocalized with calnexin but not colocalized with GM130, indicating that they were mostly retained in the ER. Cell surface biotinylation indicated that mutant neuroligin 3 and neuroligin 4X were abundant in the cell surface F I G U R E 3 HEK293 cells expressing GFP-tagged wild-type neuroligin (NL3-WT and NL4-WT), mutant neuroligin (NL3-G426S, NL4-G84R, NL4-Q162K, NL4-A283T) and positive control (NL3-R451C and NL4-R87W) were analyzed for cell surface localization. Proteins were detected in total cell lysates by western blotting with anti-GFP antibodies. Cell surface proteins were modified with membrane non-permeable reactive biotin and modified proteins were isolated on NeutrAvidin Agarose. NLs in the biotinylated fraction (surface) were analyzed by western blotting with anti-GFP antibodies. Because the four mutant proteins did not impair the folding of neuroligin 3 and neuroligin 4X and also did not inhibit their surface export, we measured the ability of these mutant proteins to bind to recombinant IgG-NX1β fusion protein. We observed that the mutant neuroligin 3 and neuroligin 4X showed a binding affinity for their cognate partner, β-neurexin, that was similar to that of wild-type neuroligin ( Figure 6 ). Therefore, neurexin-binding was not impaired by any of the four mutations. However, the two positive controls did not bind to recombinant IgG-NX1β fusion protein.
| DISCUSSION
Autism is a complex neurodevelopmental disorder in which mutations in neuroligin may play a role. In this study, we used in vitro
The four variants do not destabilize neuroligin 3 and neuroligin 4X. HEK293 cells expressing GFP-tagged wild-type neuroligin (NL3-WT and NL4-WT), mutant neuroligin (NL3-G426S, NL4-G84R, NL4-Q162K, NL4-A283T), and positive control (NL3-R451C and NL4-R87W) were treated with 20 μg/ml CHX for 0 to 12 hr (for NL3) or 0 to 24 hr (for NL4X). Inhibition of protein synthesis, and the accumulation of wild-type neuroligin, mutant neuroligin, or positive control were evaluated by Western blotting. Beta-actin was used as a loading control. assays in HEK293 cells to demonstrate that four identified neuroligin mutations did not affect protein expression or interaction with neurexin 1. We conclude that these four variants either play only a modest role in predisposition to autism, or are previously unreported infrequent polymorphisms rather than pathogenic mutations. We must bear in mind, however, that we cannot recapitulate the situation in a human patient: we were studying a single factor in isolation, ignoring other genetic, epigenetic, and environmental factors that may play a contributory role in disease causation.
In conclusion, our data indicate that our four previously described mutations in neuroligins 3 and 4X are not primary risk factors for autism.
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F I G U R E 5
The four variants do not change the degradation pathway of neuroligin 3 and neuroligin 4X. HEK293 cells expressing GFPtagged wild-type neuroligin (NL3 and NL4X), mutant neuroligin (G426S, G84R, Q162K, and A283T), or positive control (R451C and R87W) were pretreated with the proteasome inhibitor MG132 (10 μmol/L) or the lysosome inhibitor chloroquine (CQ; 100 μmol/L) for 0 hr (untreated) or 10 hr. The accumulation of wild-type neuroligin, mutant neuroligin, and positive control was evaluated by Western blotting. Beta-actin was used as a loading control. 
